Alterity Therapeutics (ATHE) Capital Expenditures (2016 - 2019)

Alterity Therapeutics has reported Capital Expenditures for 4 years, with the latest figure at $49858.4 in Q4 2019.

• On a quarterly basis, Capital Expenditures rose 2223.41% year-over-year to $49858.4 in Q4 2019; TTM through Dec 2019 was $28320.6, a 158.61% increase from a year earlier, with the FY2024 full-year figure at -$5722.0, changed N/A from the prior year.
• Capital Expenditures was $49858.4 for Q4 2019 at Alterity Therapeutics, up from -$2348.0 in the prior quarter.
• The five-year high for Capital Expenditures was $49858.4 in Q4 2019, with the low at -$16622.8 in Q4 2016.
• Average Capital Expenditures over 4 years is $7080.1, with a median of -$2457.5 recorded in 2017.
• The sharpest annual moves came in 2018 and 2019: Capital Expenditures grew 8.53% in 2018, then surged 2223.41% in 2019.
• Over 4 years, Capital Expenditures stood at -$16622.8 in 2016, then jumped by 84.56% to -$2567.1 in 2017, then advanced by 8.53% to -$2348.0 in 2018, then soared by 2223.41% to $49858.4 in 2019.
• The last three Capital Expenditures figures came in at $49858.4 (Q4 2019), -$2348.0 (Q4 2018), and -$2567.1 (Q4 2017), per Business Quant data.